From 1 June 2021, MVASI® brand for bevacizumab will replace the Avastin® brand for all PBS listed items.
This has reduced the authority level, and bevacizumab is now listed as unrestricted benefit. Authority approval isn’t required for prescribing the listed quantity and repeats.
Page last updated: 1 June 2021
This information was printed 13 September 2021 from https://www.servicesaustralia.gov.au/organisations/health-professionals/services/medicare/written-authority-required-drugs/drug-program-or-condition/glioblastoma. It may not include all of the relevant information on this topic. Please consider any relevant site notices at https://www.servicesaustralia.gov.au/individuals/site-notices when using this material.